To the full analysis
Buyback calculator for Clínica Baviera
Clínica Baviera stock: key metrics
CBAV.MCClínica Baviera had an operating margin of 27.3% and a return on invested capital (ROIC) of 46.4% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 94.5% | 30.9% | −41.4% |
| 2007 | 92.6% | 23.3% | −30.2% |
| 2008 | 91.0% | 12.9% | 8.0% |
| 2009 | 90.8% | 5.0% | 2.2% |
| 2010 | 89.4% | 8.7% | 5.8% |
| 2011 | 88.9% | 8.6% | 5.8% |
| 2012 | 89.0% | 0.7% | −0.1% |
| 2013 | 89.4% | 8.8% | 6.1% |
| 2014 | 86.3% | 6.8% | 4.9% |
| 2015 | 86.4% | 7.6% | 5.7% |
| 2016 | 87.1% | 12.7% | 8.6% |
| 2017 | 88.7% | 13.6% | 9.8% |
| 2018 | 88.3% | 15.5% | 10.8% |
| 2019 | 88.2% | 14.7% | 10.3% |
| 2020 | 87.6% | 16.7% | 11.4% |
| 2021 | 87.6% | 22.8% | 15.9% |
| 2022 | 87.1% | 20.9% | 14.9% |
| 2023 | 88.0% | 22.2% | 16.0% |
| 2024 | 88.4% | 21.2% | 15.3% |
| 2025 | 42.1% | 27.3% | 13.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | 128.2% | −60.6% |
| 2007 | −100.0% | 100.8% | −52.3% |
| 2008 | 36.7% | 34.8% | 10.9% |
| 2009 | 8.9% | 9.2% | 3.2% |
| 2010 | 23.4% | 20.6% | 9.2% |
| 2011 | 22.8% | 20.4% | 9.3% |
| 2012 | −0.4% | 1.1% | −0.2% |
| 2013 | 19.6% | 18.9% | 10.1% |
| 2014 | 20.4% | 18.2% | 8.3% |
| 2015 | 23.2% | 20.7% | 10.5% |
| 2016 | 42.8% | 35.5% | 16.9% |
| 2017 | 39.7% | 39.2% | 18.1% |
| 2018 | 41.5% | 40.1% | 21.2% |
| 2019 | 41.8% | 24.1% | 12.6% |
| 2020 | 31.3% | 19.1% | 11.5% |
| 2021 | 50.2% | 38.4% | 20.5% |
| 2022 | 43.8% | 40.5% | 19.7% |
| 2023 | 39.5% | 44.7% | 20.1% |
| 2024 | 41.5% | 38.6% | 19.0% |
| 2025 | 38.2% | 46.4% | 17.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Dec 2020)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.